Primary chemoprevention of familial adenomatous polyposis with sulindac


Published in:
The New England journal of medicine

DOI:
10.1056/NEJMoa012015

Citation for published version (APA):

General rights
It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).

Disclaimer/Complaints regulations
If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: http://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.
PRIMARY CHEMOPREVENTION OF FAMILIAL ADENOMATOUS POLYPOSIS WITH SULINDAC

FRANCIS M. GIARDIELLO, M.D., VINCENT W. YANG, M.D., PH.D., LINDA M. HYLLIND, B.S., R.N., ANNE J. KRUSH, M.S., GLORIA M. PETERSEN, Ph.D., JILL D. TRIBBATH, M.S., STEVEN PIANTADOSI, M.D., PH.D., ELIZABETH GARRETT, PH.D., DEBORAH E. GEIMAN, M.S., WALTER HUBBARD, PH.D., G. JOHAN A. OFFERHAUS, M.D., M.P.H., PH.D., AND STANLEY R. HAMILTON, M.D.

Abstract
Background Familial adenomatous polyposis is caused by a germ-line mutation in the adenomatous polyposis coli gene and is characterized by the development of hundreds of colorectal adenomas and, eventually, colorectal cancer. Nonsteroidal antiinflammatory drugs can cause regression of adenomas, but whether they can prevent adenomas is unknown.

Methods We conducted a randomized, double-blind, placebo-controlled study of 41 young subjects (age range, 8 to 25 years) who were genotypically affected with familial adenomatous polyposis but phenotypically unaffected. The subjects received either 75 or 150 mg of sulindac orally twice a day or identical-appearing placebo tablets for 48 months. The number and size of new adenomas and side effects of therapy were evaluated every four months for four years, and the levels of five major prostaglandins were measured in tissue specimens during the course of the study. Adenomas developed in 9 of 21 subjects (43 percent) in the sulindac group and 11 of 20 subjects in the placebo group (55 percent). The rate of compliance exceeded 76 percent in the sulindac group. Regression of established adenomatous polyps in patients with familial adenomatous polyposis who received sulindac, a nonsteroidal antiinflammatory drug (NSAID), was described in case reports in 1983 and 1989. We and others have confirmed this observation in randomized studies of sulindac or celecoxib, a selective inhibitor of cyclooxygenase-2. These results led us to evaluate the ability of sulindac to prevent adenomas in subjects with the genetic abnormality of familial adenomatous polyposis who were phenotypically normal. We also measured tissue prostaglandin levels in colorectal mucosa because this is a reliable means of monitoring the local effect of NSAIDs in patients with familial adenomatous polyposis.

Conclusions Standard doses of sulindac did not prevent the development of adenomas in subjects with familial adenomatous polyposis.

Methods

Study Population

The study was conducted from September 1993 to July 2001. Subjects were identified and recruited from the Johns Hopkins Polyposis Registry. Written informed consent was obtained from all subjects or their parents, and assent was obtained from subjects under 18 years of age. The protocol was approved by the Johns Hopkins Joint Committee on Clinical Investigation (the institutional review board).

The genotypic and phenotypic status of all potential subjects was assessed to determine their eligibility for the trial. All potential subjects and their parents (in the case of minors) received genetic counseling before undergoing genetic testing for APC gene mutations. Eligible subjects were older than eight years of age and had a disease-causing mutation of the APC gene but had no endoscopically detectable colorectal adenomatous polyps and no history of colonic surgery.

The following were reasons for exclusion from the study: use of an NSAID or aspirin for more than one week in the three months preceding the study, unwillingness to discontinue taking NSAIDs, absence of the use of effective birth control in girls and young women of childbearing age, pregnancy, a white-cell count of less than 4000 per cubic millimeter, a platelet count of less than 100,000 per cubic millimeter, a blood urea nitrogen level of more than 25 mg per deciliter (8.9 mmol per liter), a serum creatinine level of more than 1.5 mg per deciliter (132.6 µmol per liter), a history of peptic ulcer disease or gastrointestinal hemorrhage, a history of cancer, active bacterial infection, use of dimethyl sulfoxide, a history of aspirin allergy, or a body weight of less than 20 kg.

From the Department of Medicine (F.M.G., V.W.Y., L.M.H., A.J.K., J.D.T., D.E.G., W.H.) and the Oncology Center (F.M.G., V.W.Y., S.P., E.G.), Johns Hopkins University School of Medicine, Baltimore; Mayo Clinic, Rochester, Minn. (G.M.P.); the Department of Pathology, Academic Medical Center, Amsterdam (G.I.A.O.); and the Division of Pathology and Laboratory Medicine, University of Texas M.D. Anderson Cancer Center, Houston (S.R.H.).
Study Design

The sponsor generously supplied both sulindac and placebo but was not otherwise involved in the design or conduct of the study. Data were held by the principal investigator.

Forty-one eligible subjects entered this double-blind, placebo-controlled trial. They were randomly assigned to receive sulindac orally twice a day for four years or identical-appearing placebo tablets. The sulindac dose was calculated on the basis of body weight and adjusted according to changes in weight during the course of the study. The 11 subjects in the sulindac group who weighed 20 to 44 kg at the beginning of the study received 75 mg of sulindac orally twice a day, and the 10 who weighed more than 44 kg took 150 mg of sulindac twice a day. By the end of the study, all but three subjects were receiving the higher dose. Compliance with treatment was assessed by means of pill counts, review of subjects’ diaries, and telephone calls every other week.

The development of rectosigmoid adenomatous polyps was assessed by sigmoidoscopy with an Olympus flexible video sigmoidoscope. One investigator, who did not review the records of previous examinations, made all the assessments. Evaluations were performed before treatment with sulindac or placebo was begun (month 0) and every 4 months after treatment was initiated, for a total of 48 months. At each examination, the endoscopist counted the total number of polyps in the circumference of the colon from 20 cm to the anal verge, and the examination was recorded on videotape. The diameter of up to five polyps just distal to 20 cm was measured in millimeters with a graduated scale passed through the biopsy channel of the sigmoidoscope. These measurements were averaged to determine the mean size of each subject’s polyps.

Evaluation of Safety

Adverse effects were monitored by means of telephone interviews every two to four weeks and at each four-month visit. A complete blood count was obtained and levels of glucose, blood urea nitrogen, serum creatinine, serum electrolytes, and bilirubin were measured at each visit. Adverse events were graded in accordance with the Common Toxicity Criteria of the National Cancer Institute.12 On this scale, a score of 0 indicates no adverse effects and a score of 5 life-threatening effects.

Measurement of Prostaglandin Levels

Biopsy specimens of the rectal mucosa were obtained before the initiation of treatment (month 0), at four months, and at one, two, three, and four years with standard biopsy forceps through a flexible sigmoidoscope. Tissue specimens were obtained from the normal-appearing mucosa 20 cm from the anal verge, snap-frozen in liquid nitrogen, and stored at −70°C until further analysis. Specimens were coded to disguise the subjects’ treatment assignment.

The total number of polyps in the sulindac group and the placebo group and in subjects in the sulindac group in whom polyps developed and those in the sulindac group who were free of polyps. The mean percent change was calculated as the mean of prostaglandin levels at four months and one, two, three, and four years divided by the base-line prostaglandin level. All P values were two-sided. We also used nonparametric tests in the place of t-tests and confirmed the results.

RESULTS

Demographic Characteristics

All 41 eligible subjects had an APC gene mutation, as did their parents with familial adenomatous polyposis. Of these 41 subjects, 21 were randomly assigned to receive sulindac and 20 to receive placebo. There were no significant differences in demographic characteristics between the two groups (Table 1). By the end of the study, five subjects in the sulindac group had been withdrawn. Three were withdrawn...
because of an increasing number of polyps, and they were referred for surgical consultation. One had persistent neutropenia, and one was unable to make scheduled visits. Of the 20 subjects in the placebo group, 6 were withdrawn: 4 because of an increasing number of polyps (they were referred for surgical consultation), and 2 because they were unable to make scheduled visits.

### Compliance and Adverse Events

The mean (±SD) rate of compliance with treatment was 86.9±7.5 percent among patients in the sulindac group and 81.7±10.4 percent among patients in the placebo group. All subjects in the sulindac group took more than 76 percent of the scheduled doses of medication.

**Compliance and Adverse Events**

The mean (±SD) rate of compliance with treatment was 86.9±7.5 percent among patients in the sulindac group and 81.7±10.4 percent among patients in the placebo group. All subjects in the sulindac group took more than 76 percent of the scheduled doses of medication.

Treatment with sulindac for a four-year period was well tolerated. Few adverse events were reported, and 93 percent of these were minimal (grade 1) or mild (grade 2) (Table 2). Only one subject was withdrawn

### Table 2. Incidence and Severity of Adverse Events.*

<table>
<thead>
<tr>
<th>ADVERSE EVENT</th>
<th><strong>SULINDAC GROUP</strong> (N=21)</th>
<th><strong>PLACEBO GROUP</strong> (N=20)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>no. (%)</td>
<td></td>
</tr>
<tr>
<td>Grade 2 leukopenia</td>
<td>1 (5)†</td>
<td>0</td>
</tr>
<tr>
<td>Dermatologic</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grade 2 photosensitivity</td>
<td>0</td>
<td>1 (5)</td>
</tr>
<tr>
<td>Rash</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grade 1</td>
<td>1 (5)‡</td>
<td></td>
</tr>
<tr>
<td>Grade 2</td>
<td>1 (5)§</td>
<td></td>
</tr>
<tr>
<td>Gastrointestinal</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grade 1 diarrhea</td>
<td>1 (5)¶</td>
<td>0</td>
</tr>
<tr>
<td>Grade 2 vomiting</td>
<td>1 (5)</td>
<td>1 (5)</td>
</tr>
<tr>
<td>Hemorrhagic</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grade 1 epistaxis</td>
<td>1 (5)</td>
<td>0</td>
</tr>
<tr>
<td>Grade 2 hematuria</td>
<td>1 (5)††</td>
<td>0</td>
</tr>
<tr>
<td>Grade 2 vaginal bleeding</td>
<td>1 (5)**</td>
<td></td>
</tr>
<tr>
<td>Grade 2 hyperbilirubinemia</td>
<td>1 (5)††</td>
<td>1 (5)</td>
</tr>
<tr>
<td>Grade 4 sensory neuropathy</td>
<td>0</td>
<td>1 (5)</td>
</tr>
<tr>
<td>Grade 2 blurred vision</td>
<td>0</td>
<td>1 (5)</td>
</tr>
<tr>
<td>Pain</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abdominal pain</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grade 1</td>
<td>0</td>
<td>2 (10)</td>
</tr>
<tr>
<td>Grade 2</td>
<td>1 (5)§‡</td>
<td>1 (5)</td>
</tr>
<tr>
<td>Grade 3</td>
<td>1 (5)‡‡</td>
<td></td>
</tr>
<tr>
<td>Grade 1 earache</td>
<td>1 (5)</td>
<td>0</td>
</tr>
<tr>
<td>Grade 2 headache</td>
<td>1 (5)</td>
<td>1 (5)</td>
</tr>
<tr>
<td>Grade 2 myalgia</td>
<td>0</td>
<td>1 (5)</td>
</tr>
<tr>
<td>Influenza-like syndrome§§</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grade 1</td>
<td>6 (29)§</td>
<td>3 (15)</td>
</tr>
<tr>
<td>Grade 2</td>
<td>4 (19)</td>
<td>5 (25)</td>
</tr>
</tbody>
</table>

*All adverse events are reported. A grade of 1 indicates minimal adverse effects, a grade of 2 mild effects, a grade of 3 moderate effects, and a grade of 4 severe effects.

†A hematologic workup revealed no clear cause.

‡The rash was associated with a viral infection.

§The rash was associated with mild ileus.

¶The diarrhea was due to lactose intolerance.

‖The hematuria was due to a urinary tract infection.

**The subject’s sister and mother had a similar history.

††Hyperbilirubinemia was due to Gilbert’s disease.

‡‡The abdominal pain was due to acute cholecystitis. The subject had a family history of cholecystitis at a young age.

§§The syndrome was characterized by fever and myalgia, with or without nausea, vomiting, diarrhea, headache, and abdominal cramps.
from the study because of possible drug-induced persistent neutropenia. The incidence of any adverse event did not differ significantly between the sulindac group and the placebo group.

Efficacy

The number of subjects in whom one or more adenomas developed during the study did not differ significantly between the groups (Table 3). By the end of the study, adenomas had developed in 9 of the 21 subjects in the sulindac group (43 percent) and 11 of the 20 subjects in the placebo group (55 percent) (P=0.54). The groups did not differ significantly with respect to the number of subjects with multiple adenomas, large adenomas, or advanced adenomas (tubulovillous or villous adenomas) (Table 3).

Among the patients who received treatment for 40 months or more, there were no significant differences between the groups in the mean number or size of polyps (Table 4). According to the intention-to-treat analysis, the overall difference in the number of polyps between the sulindac group and the placebo group was 0.52 (95 percent confidence interval, −0.29 to 2.73; P=0.27). Similarly, the overall difference in the size of polyps was 0.24 (95 percent confidence interval, −0.11 to 0.75; P=0.21).

Random-effects linear longitudinal analysis revealed that treatment with sulindac did not influence the number of polyps (β=0.08, P=0.23) or the size of polyps (β=0.06, P=0.13) (Fig. 1).

Prostaglandin Levels

There was no significant difference between the sulindac and placebo groups in the base-line levels...
TABLE 5. MEAN PERCENT CHANGES FROM BASE LINE IN PROSTAGLANDIN LEVELS IN COLORECTAL MUCOSA.*

<table>
<thead>
<tr>
<th>Prostaglandin</th>
<th>Sulindac Group (N=21)</th>
<th>Placebo Group (N=20)</th>
<th>P VALUE†</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>percent change from base line</td>
<td>percent change from base line</td>
<td></td>
</tr>
<tr>
<td>Prostaglandin D₂</td>
<td>69.4±29.2</td>
<td>209.6±169.5</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Prostaglandin E₂</td>
<td>80.8±53.5</td>
<td>233.3±226.8</td>
<td>0.006</td>
</tr>
<tr>
<td>Prostaglandin F₂α</td>
<td>90.5±50.5</td>
<td>203.8±154.8</td>
<td>0.004</td>
</tr>
<tr>
<td>Thromboxane B₂</td>
<td>94.0±85.0</td>
<td>245.7±198.5</td>
<td>0.004</td>
</tr>
<tr>
<td>6-Keto-prostaglan-</td>
<td>110.9±94.5</td>
<td>208.4±202.7</td>
<td>0.06</td>
</tr>
<tr>
<td>din F₁α</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Plus–minus values are means ±SD. Base-line values were 100 percent.
†The t-test was used to calculate P values.

of prostaglandins (data not shown). After treatment, levels of prostaglandins D₂, E₂, and F₂α and thromboxane B₂ were significantly lower in the sulindac group than in the control group (Table 5), providing additional evidence of compliance with treatment.

DISCUSSION

In this randomized, double-blind, placebo-controlled study, standard doses of sulindac did not prevent polyps in subjects who were genotypically affected with familial adenomatous polyposis by those who were phenotypically unaffected initially. All subjects were carriers of APC gene mutations known to cause familial adenomatous polyposis in their parents, and there were no significant differences in base-line characteristics between the sulindac and placebo groups.

Compliance with treatment was excellent in the sulindac group. In addition, prostaglandin levels in the colorectal mucosa were significantly lower among subjects in this group than among those in the placebo group, verifying compliance with treatment. Although the amounts of sulindac we used are similar to those that have been shown to cause regression of established adenomas and reduce local prostaglandin levels, higher doses might be appropriate if another trial is planned.3-10

Evidence that sulindac has a short-lived effect on established polyps in patients with familial adenomatous polyposis has been reported. We showed that the rate of regression of adenomas was greater after six months of sulindac treatment than after nine months,9 and in some patients who had undergone ileorectal anastomosis, long-term use of sulindac resulted in the development of resistance to this medication.19,20 Moreover, colorectal cancer has developed in the rectal segment in at least three patients with familial adenomatous polyposis during maintenance therapy with sulindac.14,21,22

The lack of efficacy of primary chemoprevention could have been due to resistance to sulindac. Notably, combination treatment was more effective than sulindac alone in preventing adenomas in a murine model of familial adenomatous polyposis.23 The use of multiple drugs for both primary chemoprevention and the regression of adenomas in patients with familial adenomatous polyposis and those with hereditary nonpolyposis colorectal cancer deserves further evaluation.

In summary, our results do not provide support for the use of NSAIDs such as sulindac for the primary treatment of familial adenomatous polyposis. Prophylactic colectomy remains the treatment of choice to prevent colorectal cancer in patients with this disorder.

Supported in part by the Clayton Fund, the John G. Rangos, Sr., Charitable Foundation, and Merck and by grants (CA 53801, CA 63721, and P50 CA 62924-04) from the National Institutes of Health.

We are indebted to Ms. Linda Welch, Ms. Lilly Chua, Ms. Marianne Villani, Ms. Kathy Romans, and Dr. Mary C. Corretti for technical support.

REFERENCES
